Pharmaceuticals, Biotechnology & Life Sciences

Insider sales at Puma Biotechnology spike amid modest price rise—does this signal confidence or caution? Explore the insider moves, market sentiment, and what it means for investors.

Insightful look at Adaptive Biotechnologies’ insider sale: rule‑based 10k shares at $16.44, showing disciplined divestment yet strong long‑term stake.

Codexis insider sales raise questions as CSO sells shares amid Axolabs partnership – explore what this means for the company’s RNA‑tech future and investor confidence.

Arrowhead’s CMO flips from selling to buying, buying 75,000 shares at a zero‑price entry, signaling renewed confidence in its RNAi obesity pipeline and upcoming capital raise.

Insider CFO Prasad Raju’s 10b5‑1 trades show confidence in CRISPR Therapeutics; buying near $45‑$44 while selling above $60 signals a bullish, medium‑term outlook for the gene‑editing stock.

Column Group III GP’s latest $19.89 buy of 15,100 Surrozen shares shows long‑term confidence in its biotech pipeline, hinting at upside if clinical milestones hit.

Alkermes insider buys 5,000 shares at $19.34 under a 10‑b‑plan, betting on a short‑term rise as the company’s Breakthrough Therapy for alixorexton gains momentum.

PTC insider sales are routine tax‑cover events, not confidence shifts; investors should focus on Sephiencet approvals and pipeline progress.

Insider sale by Borgeson Blake at Recursion Pharmaceuticals is a routine 10b5‑1 plan move; it doesn’t signal a downgrade, but watch the AI‑driven drug pipeline and earnings outlook for investor insight.

Insider buying at Zentalis signals confidence in its oncology pipeline, especially Azenosertib—may lift stock beyond 52‑week highs amid volatile pricing.